Foghorn Therapeutics (FHTX) FCF Margin (2020 - 2026)

Foghorn Therapeutics' FCF Margin history runs 7 years deep, the most recent figure standing at 773.37% for Q1 2026.

• On a quarterly basis, FCF Margin fell 37021.0% year-over-year to 773.37% in Q1 2026; TTM through Mar 2026 was 309.56%, a 9830.0% increase from a year earlier, with the FY2025 full-year figure at 278.56%, up 16969.0% from the prior year.
• FCF Margin eased to 773.37% in Q1 2026 per FHTX's latest filing, from 240.85% in the prior quarter.
• Across five years, FCF Margin topped out at 6920.59% in Q1 2022 and bottomed at 875.28% in Q4 2024.
• The 5-year median for FCF Margin is 403.16% (2025), against an average of 33.21%.
• Across the five-year window, FCF Margin jumped 5027072 bps in 2022 and sank 751350 bps in 2023, its largest moves.
• Year by year, FCF Margin stood at 690.25% in 2022, then grew by 28 bps to 497.61% in 2023, then slumped by 76 bps to 875.28% in 2024, then soared by 72 bps to 240.85% in 2025, then slumped by 221 bps to 773.37% in 2026.
• Per Business Quant, the three latest FHTX FCF Margin figures stand at 773.37% (Q1 2026), 240.85% (Q4 2025), and 231.33% (Q3 2025).